You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物-B(01877.HK)公佈年度業績 研發開支大增75.8% 特瑞普利收入達7.74億元
格隆匯 03-27 22:57

格隆匯3月27日丨君實生物-B(01877.HK)發佈公告,截至2019年12月31日止年度,公司收入7.75億元人民幣,同比增長829倍;公司擁有人應占年內虧損7.44億元,虧損同比擴大3.8%;每股虧損0.95元。

由於就研究及開發持續投資,公司的研發開支為人民幣9.46億元,較2018年增加75.8%,主要為關鍵臨牀試驗的不斷推進,及合作研發及授權許可項目的引進則將公司研發管線拓展至小分子藥物及抗體藥物偶聯物。截至目前,公司共有21項在研產品,13項是由公司自主研發的原創新藥,8項與合作伙伴共同開發。

於報告期內,公司在產品商業化、臨牀試驗、管線擴張、生產基地建設等方面取得重大進展,截至本公告日期,公司利用公司的核心平台,通過與第三方合作,開發包括21種遴選藥品的產品管線,涵蓋了未被滿足醫療需求相關的各種疾病領域。

報告期內,公司核心產品特瑞普利(商品名:拓益)的銷售收入達人民幣7.74億元。銷售毛利率88.3%,銷售開支佔銷售收入佔比約41.3%。截至本公告日期,同時進行14項關鍵的註冊臨牀試驗,涵蓋特瑞普利的廣泛適應症,包括:尿路上皮癌、鼻咽癌、黑色素瘤、非小細胞肺癌、小細胞肺癌、三陰性乳腺癌、食管癌、肝細胞癌、胃癌及腎細胞癌。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account